AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Agios Pharm (NASDAQ:AGIO)
34.47 USD
-0.030 0.087%| Previous Close (in USD) | 34.5 |
|---|---|
| Change | -0.030 0.087% |
| 52 W H/L (in USD) | 62.580/20.960 |
| EBITDA (in USD) | -401.288M |
| PE Ratio | 4.17 |
| Volume | 170348 |
| Diluted Eps TTM | 11.66 |
| Total Assets (in USD) | 937.118M |
|---|---|
| Total Liabilities (in USD) | 126.099M |
| Revenue TTM (in USD) | 32.871M |
| Cash (in USD) | 88.205M |
| Market Cap (in USD) | 2,773.949 M |
| Revenue Per Share TTM | 0.582 |
| Gross Profit TTM (in USD) | 12.536M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees: 383
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Bruce D. Car DACVP, Ph.D. | Consultant | 1961 |
| 2. | Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of R&D | 1980 |
| 3. | Ms. Richa Poddar | Chief Commercial Officer | 1982 |
| 4. | Mr. Brian M. Goff M.B.A. | CEO & Director | 1969 |
| 5. | Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1949 |
| 6. | Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1946 |
| 7. | Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | 1953 |
| 8. | Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1956 |
| 9. | Ms. Cecilia Jones | Chief Financial Officer | 1975 |
| 10. | Mr. T. J. Washburn Jr. | Principal Accounting Officer | 1981 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -231.801M | -356.51M | -327.37M | -411.472M | -346.028M |
| Minority Interest | - | - | - | - | - |
| Net Income | -74.555M | 1604.715M | -335.218M | -396.611M | -346.028M |
| Selling General Administrative | 121.673M | 121.445M | 149.07M | 132.034M | 114.145M |
| Gross Profit | 12.536M | 0.041M | 200.391M | 116.595M | 92.99M |
| Reconciled Depreciation | 8.564M | 9.24M | 9.984M | 8.087M | 7.172M |
| Ebit | -389.047M | -378.418M | -316.149M | -426.333M | -369.651M |
| Ebitda | -526.751M | -385.057M | -309.538M | -418.246M | -362.479M |
| Depreciation And Amortization | -137.704M | -6.639M | 6.611M | 8.087M | 7.172M |
| Operating Income | -389.047M | -378.418M | -316.149M | -426.333M | -362.479M |
| Other Operating Expenses | 403.287M | 378.418M | 519.345M | 544.245M | 456.866M |
| Interest Expense | 12.793M | 0.836M | 17.832M | 14.861M | 16.451M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 12.793M | 0.836M | 6.611M | 14.861M | 16.451M |
| Net Interest Income | 12.793M | 0.836M | -11.221M | 14.861M | 16.451M |
| Income Tax Expense | -157.246M | -1977.94M | 7.848M | -14.861M | 32.902M |
| Total Revenue | 14.24M | 0.041M | 203.196M | 117.912M | 94.387M |
| Total Operating Expenses | 401.583M | 378.418M | 516.54M | 542.928M | 455.469M |
| Cost Of Revenue | 1.704M | 0.001M | 2.805M | 1.317M | 1.397M |
| Total Other Income Expense Net | 157.246M | 21.908M | -11.221M | 14.861M | 16.451M |
| Net Income From Continuing Ops | -231.801M | -356.51M | -309.538M | -411.472M | -346.028M |
| Net Income Applicable To Common Shares | -231.801M | 1604.715M | -327.37M | -411.472M | -346.028M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 937.118M | 1238.718M | 1437.736M | 852.952M | 890.741M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 35.021M | 38.955M | 11.816M | -73.957M | 24.177M |
| Total Liab | 126.099M | 137.904M | 145.761M | 453.452M | 250.213M |
| Total Stockholder Equity | 811.019M | 1100.814M | 1291.975M | 399.5M | 640.528M |
| Other Current Liab | 43.167M | 30.35M | 31.967M | 60.14M | 53.142M |
| Common Stock | 0.072M | 0.071M | 0.071M | 0.069M | 0.068M |
| Capital Stock | 0.072M | 0.071M | 0.071M | 0.069M | 0.068M |
| Retained Earnings | -822.649M | -470.561M | -238.76M | -1843.475M | -1516.105M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 3.956M | 2.9M | 1.125M | - |
| Cash | 88.205M | 139.259M | 203.126M | 127.436M | 80.931M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 67.955M | 62.629M | 59.826M | 94.394M | 92.886M |
| Current Deferred Revenue | - | - | - | - | 10.933M |
| Net Debt | -16.209M | -53.6M | -106.032M | -22.237M | 32.731M |
| Short Term Debt | 15.008M | 13.663M | 11.159M | 7.41M | 6.915M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 71.996M | 85.659M | 97.094M | 105.199M | 113.662M |
| Other Stockholder Equity | 1634.037M | 1583.839M | 1531.862M | 2242.801M | 2156.363M |
| Property Plant Equipment | - | 22.987M | 28.923M | 32.291M | 31.472M |
| Total Current Assets | 833.835M | 832.772M | 1064.231M | 636.677M | 611.704M |
| Long Term Investments | 29.435M | 313.874M | 266.375M | 97.608M | 152.929M |
| Short Term Investments | 688.723M | 643.86M | 816.892M | 445.493M | 483.946M |
| Net Receivables | 2.81M | 2.206M | 4.378M | 25.399M | 15.319M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 19.076M | 8.492M | 16.19M | 14.698M | 7.331M |
| Accounts Payable | 9.78M | 18.616M | 16.7M | 26.844M | 21.896M |
| Accumulated Other Comprehensive Income | -0.441M | -12.535M | -1.198M | 0.105M | 0.202M |
| Non Currrent Assets Other | 4.057M | 3.956M | 2.9M | 1.125M | 94.636M |
| Non Current Assets Total | 103.283M | 405.946M | 373.505M | 216.275M | 279.037M |
| Capital Lease Obligations | 71.996M | 85.659M | 97.094M | 105.199M | 113.662M |
| Long Term Debt Total | - | - | - | - | 0.673M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 243.261M | -548.417M | 90.655M | 103.611M | -266.839M |
| Total Cashflows From Investing Activities | 243.261M | 1248.778M | 75.746M | 91.44M | -273.825M |
| Total Cash From Financing Activities | 2.35M | -765.768M | 261.518M | 289.611M | 546.024M |
| Net Income | -231.801M | -356.51M | -327.37M | -411.472M | -346.028M |
| Change In Cash | -63.867M | 75.69M | 46.505M | 10.429M | -32.222M |
| Begin Period Cash Flow | 203.126M | 127.436M | 80.931M | 70.502M | 102.724M |
| End Period Cash Flow | 139.259M | 203.126M | 127.436M | 80.931M | 70.502M |
| Total Cash From Operating Activities | -309.478M | -407.32M | -290.759M | -370.622M | -304.421M |
| Depreciation | 8.564M | 9.24M | 9.984M | 8.087M | 7.172M |
| Other Cashflows From Investing Activities | 132.748M | 1802.936M | 1802.936M | 103.611M | -266.839M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -8.492M | -8.492M | -7.367M | -6.462M | -0.869M |
| Sale Purchase Of Stock | 2.681M | -802.486M | 11.317M | 289.724M | 546.024M |
| Other Cashflows From Financing Activities | 2.681M | 37.296M | 261.854M | 12.523M | 29.818M |
| Capital Expenditures | 4.881M | 5.741M | 14.909M | 12.171M | 6.986M |
| Change In Working Capital | -16.433M | -36.822M | -71.037M | -45.999M | -35.105M |
| Other Non Cash Items | -119.104M | 9.537M | 19.52M | 8.532M | -3.817M |
| Free Cash Flow | -314.359M | -413.061M | -305.668M | -382.793M | -311.407M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Explorer Inv | 8 months ago | 493427 |
| 2. | US Small-Cap Growth II Equity Comp | 8 months ago | 482236 |
| 3. | T. Rowe Price New Horizons | 7 months ago | 481923 |
| 4. | BB Biotech AG Ord | 8 months ago | 3735915 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1773857 |
| 6. | iShares Russell 2000 ETF | 6 months ago | 1596567 |
| 7. | Vanguard Small Cap Index | 7 months ago | 1425876 |
| 8. | Delaware Small Cap Core I | 7 months ago | 1379776 |
| 9. | T. Rowe Price Health Sciences | 7 months ago | 1321166 |
| 10. | SPDR® S&P Biotech ETF | 6 months ago | 963246 |
| 11. | Polar Capital Biotech S Inc | 7 months ago | 960418 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 847202 |
| 13. | DWS Vermögensbildungsfonds I LD | 7 months ago | 805527 |
| 14. | Vanguard Small Cap Growth Index Inv | 7 months ago | 783609 |
| 15. | JPMorgan Small Cap Growth A | 7 months ago | 606267 |
| 16. | BNP Paribas Health Cr Innovtr Cl Cap | 7 months ago | 597761 |
| 17. | Fidelity Small Cap Index | 8 months ago | 574836 |
| 18. | JPM Global Healthcare C (acc) USD | 7 months ago | 563619 |
| 19. | iShares Russell 2000 Value ETF | 6 months ago | 556105 |
| 20. | Pictet Biopharmaceutical Mother | 1 year ago | 494076 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Farallon Capital Management, L.L.C. | 8 months ago | 5660866 |
| 2. | Vanguard Group Inc | 8 months ago | 5545982 |
| 3. | BlackRock Inc | 11 months ago | 4859002 |
| 4. | Bellevue Group AG | 8 months ago | 3735915 |
| 5. | T. Rowe Price Associates, Inc. | 8 months ago | 2832512 |
| 6. | State Street Corp | 8 months ago | 2331433 |
| 7. | Armistice Capital, LLC | 8 months ago | 2207070 |
| 8. | JPMorgan Chase & Co | 8 months ago | 1712990 |
| 9. | Macquarie Group Ltd | 8 months ago | 1690801 |
| 10. | Dimensional Fund Advisors, Inc. | 8 months ago | 1562183 |
| 11. | Geode Capital Management, LLC | 8 months ago | 1357531 |
| 12. | Marshall Wace Asset Management Ltd | 8 months ago | 1263285 |
| 13. | Bvf Inc | 8 months ago | 1190107 |
| 14. | Polar Capital Holdings PLC | 8 months ago | 1002036 |
| 15. | BNP Paribas Investment Partners SA | 8 months ago | 907044 |
| 16. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 8 months ago | 882731 |
| 17. | Fisher Asset Management, LLC | 8 months ago | 855328 |
| 18. | Vestal Point Capital LP | 8 months ago | 760000 |
| 19. | Rock Springs Capital Management LP | 8 months ago | 699389 |
| 20. | Deutsche Bank AG | 8 months ago | 669615 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...